Eli Lilly stock has delivered a very large 5-year return, yet the current checks send a mixed signal, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while the broader valuation score leans expensive.

• Eli Lilly has returned about 4.1x over the past 5 years, which puts more pressure on today’s valuation to be supported by future cash flows.
• Expectations around obesity and oncology drug growth can support the current price, while ongoing regulatory and pricing pressures may limit how much value investors are willing to ascribe to that pipeline.
• The stock only passes 2 of 6 valuation checks, which means the broader set of tests suggests Eli Lilly is not an obvious bargain even with an intrinsic value estimate that screens as undervalued on the DCF model.

The issue now is whether Eli Lilly’s current share price already reflects the cash flows implied by that DCF-based intrinsic value estimate or still leaves a meaningful margin of safety.

Is Eli Lilly a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Eli Lilly’s future cash generation could be worth today. The model uses latest twelve month free cash flow of about $8.6b in $ and applies a growing cash flow profile to project future free cash flows, which results in an estimated intrinsic value of about $1,644 per share.

This implies the stock currently appears approximately 29.7% undervalued relative to the current share price, following a strong multi year run. The recent surge in Eli Lilly shares on obesity drug momentum and upbeat analyst views helps explain why the market price already appears rich on simple multiples. However, the DCF output indicates that the projected cash flows support a higher value than today’s quote.

Putting it together, the DCF view is that Eli Lilly stock currently appears undervalued relative to its estimated intrinsic worth.

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 29.7%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Does Eli Lilly Look Fairly Valued on Earnings?

P/E is a useful anchor for Eli Lilly because earnings are a key focus for mature, profitable pharmaceutical companies. Eli Lilly trades on a P/E of about 40.8x, which is well above the Pharmaceuticals industry average of 15.1x and also higher than the peer group average of 24.5x, so you are paying a clear premium for each dollar of current earnings.

The Fair P/E Ratio model, which adjusts for Eli Lilly’s size, profitability profile, sector and risk, points to a “fair” multiple of roughly 39.2x. That is only slightly below where the stock currently sits, suggesting the market is broadly aligned with what this framework implies rather than stretching far beyond it.

On this earnings multiple, Eli Lilly stock appears priced roughly in line with what the tailored fair value model would suggest, so it screens as about fairly valued on P/E.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Eli Lilly pick up where the valuation checks leave off by spelling out what would need to happen to Eli Lilly’s growth, margins and earnings for the stock to be worth materially more or less than today’s price. Rather than relying on a single multiple or model, each narrative lays out its own fair value assumptions so you can compare those with Eli Lilly’s actual results over time.

The community is split on Eli Lilly, with one camp focused on the long runway for GLP 1 drugs and another wary of pricing and concentration risks.

Bull case: roughly fairly valued

"Market penetration for all GLP-1 drugs is only at 4% of target audience of 100 to 120 million people in the USA alone…"

Bear case: 29% overvalued

"The likelihood of significant drug pricing reforms in the U.S., combined with initiatives to increase pricing parity between the U.S. and Europe, threatens to sharply limit Eli Lilly's future pricing power…"

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

The Bottom Line

For Eli Lilly, the Discounted Cash Flow (DCF) estimate points to meaningful upside, while the tailored P/E framework says the stock is already priced about right for its current earnings power. That split reflects a market that is paying up for growth and sentiment, even as the intrinsic value view leans on the timing and durability of future cash flows. The broader valuation checks remain weak, so this is not a clear-cut bargain despite the DCF signal. The crux from here is whether Eli Lilly can sustain obesity and oncology cash flows at a level that justifies both the premium multiple and the intrinsic value estimate.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.